Standard first-line therapy for persistent, recurrent, or metastatic cervical cancer is platinum-based chemotherapy, with a preferred regimen of a platinum compound (cisplatin or carboplatin) and ...

The phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles plus platinum-based chemotherapy, with or without bevacizumab, showed ...